Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...302303304305306307308309310311312...401402»
  • ||||||||||  rivaroxaban / Bayer, Generic mfg., apixaban / Generic mfg.
    Clinical, Journal:  Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. (Pubmed Central) -  Dec 23, 2020   
    Consequently, in the presence of potential DDIs through CYP3A4, and/or P-gp, LMWHs remain the first-line anticoagulant of choice for the long-term treatment of CAT. Multidisciplinary consultation meetings and therapeutic patient education should be emphasized in the complex management of CAT.
  • ||||||||||  Review, Journal:  Nutritional Status as a Mediator of Fatigue and Its Underlying Mechanisms in Older People. (Pubmed Central) -  Dec 23, 2020   
    Modifications in food intake and body composition changes seem to influence the perception of fatigue, probably through the mechanisms of inflammation and/or mitochondrial dysfunction. Here, we present an overview on the mechanisms that may mediate fatigue levels in old age, with a special focus on nutrition.
  • ||||||||||  Biomarker, Clinical, Journal:  The effect of Korean Red Ginseng on sarcopenia biomarkers in type 2 diabetes patients. (Pubmed Central) -  Dec 23, 2020   
    Twenty-four week administration of KRG in diabetes patients resulted in a significant improvement in follistatin and SHBG levels, especially in old postmenopausal women. A further, larger population study with a longer follow-up period is warranted to verify and understand the effects of KRG on sarcopenia.
  • ||||||||||  Journal:  The diagnostic value of the Short Physical Performance Battery for sarcopenia. (Pubmed Central) -  Dec 23, 2020   
    The SPPB displayed acceptable value in diagnosing older adults with severe sarcopenia. Moreover, the high sensitivity of the SPPB when using the cut-point of ≤8 suggests it may be a favorable screening tool for sarcopenia in clinical settings where ALM measurements are not available.
  • ||||||||||  Journal:  Lkb1 suppresses amino acid-driven gluconeogenesis in the liver. (Pubmed Central) -  Dec 22, 2020   
    Hepatic Lkb1 deletion is associated with major changes in whole-body metabolism, leading to a lower lean body mass and, in the longer term, sarcopenia and cachexia, as a consequence of the diversion of amino acids to liver metabolism at the expense of muscle. Using genetic, proteomic and pharmacological approaches, we identify the aminotransferases and specifically Agxt as effectors of the suppressor function of Lkb1 in amino acid-driven gluconeogenesis.
  • ||||||||||  Review, Journal:  The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. (Pubmed Central) -  Dec 22, 2020   
    There are also changes in NMJ structure and function in motor neuron disease, spinal muscle atrophy and sarcopenia that are likely to be secondary but might provide treatment targets. The NMJ is one of the best studied and most disease-prone synapses in the nervous system and it is amenable to in vivo and ex vivo investigation and to systemic therapies that can help restore normal function.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Retrospective data, Journal:  Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. (Pubmed Central) -  Dec 20, 2020   
    Comparable to MRI, skeletal muscle fat content can be quantified from CT, which might have an impact of analyses in larger cohort studies, particularly in sarcopenia patients. Cancer cachexia may be associated with worse clinical outcomes in patients with AGC treated with nivolumab.
  • ||||||||||  Review, Journal:  Exploring the Impact of Obesity on Skeletal Muscle Function in Older Age. (Pubmed Central) -  Dec 19, 2020   
    In addition, whilst highly complex, we attempt to provide an updated summary for the role of obesity from a protective and damaging perspective on muscle mass and function in older age. We conclude with a brief discussion on treatment of sarcopenia and obesity and a summary of future directions for this research field.
  • ||||||||||  Journal:  Sarcopenic obesity: etiology and lifestyle therapy. (Pubmed Central) -  Dec 18, 2020   
    Ultrasound echogenicity has been demonstrated to be an important surrogate marker of muscle health, but difficulties with reproducibility preclude its widespread clinical use. The deficiency of muscle mass in obese elderly subjects will be one of the health challenges of the future to reduce the risk of chronic diseases.